TY  - JOUR
AU  - Seferović, Jelena
AU  - Lalić, Nebojša M.
AU  - Floridi, Federico
AU  - Tesić, Milorad
AU  - Seferović, Petar M.
AU  - Giga, Vojislav
AU  - Lalić, Katarina
AU  - Jotić, Aleksandra
AU  - Jovičić, Snežana
AU  - Colak, Emina
AU  - Salerno, Gerardo
AU  - Cardelli, Patrizia
AU  - Di Somma, Salvatore
PY  - 2014
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/2074
AB  - Background: Galectin-3 is a protein widely distributed in the heart, brain and blood vessels, and has a regulatory role in inflammation, immunology and cancer. Many studies demonstrated that the increased level of galectin-3 is associated with progressive fibrosis and stiffening of the myocardium. The aim of this study was to investigate the role of galectin-3 in patients with type 2 diabetes (T2D) and/or arterial hypertension (HT). Methods: Study population included 189 patients, with no coronary artery disease, divided into three groups: group 1 (T2D), group 2 (T2D+HT), and group 3 (HT). All subjects underwent routine laboratory tests, as well as specific biomarkers assessment [galectin-3, glycosylated hemoglobin (HbA(1c)), N- terminal fragment B-type natriuretic peptide (NT-proBNP)]. Cardiological evaluation included physical examination, transthoracic tissue Doppler echocardiography and stress echocardiography. Results: The results of this study demonstrated significantly increased levels of galectin-3, blood glucose, and HbA(1c) in group 2. Also, echocardiographicaly, left ventricular (LV) diameters and IVS thickness were increased in this group of patients. Furthermore, in the same cohort a positive correlation between galectin-3 and NT-pro BNP, and galectin-3 and LV mass were demonstrated. In addition, a negative correlation between galectin-3 and LV end-diastolic diameter was revealed. Conclusions: This study revealed that levels of galectin-3 were higher in patients with both T2D and HT, and correlated with LV mass, indicating the potential role of this biomarker for early detection of myocardial structural and functional alterations.
PB  - Walter de Gruyter Gmbh, Berlin
T2  - Clinical Chemistry and Laboratory Medicine
T1  - Structural myocardial alterations in diabetes and hypertension: the role of galectin-3
VL  - 52
IS  - 10
SP  - 1499
EP  - 1505
DO  - 10.1515/cclm-2014-0265
ER  - 

@article{
author = "Seferović, Jelena and Lalić, Nebojša M. and Floridi, Federico and Tesić, Milorad and Seferović, Petar M. and Giga, Vojislav and Lalić, Katarina and Jotić, Aleksandra and Jovičić, Snežana and Colak, Emina and Salerno, Gerardo and Cardelli, Patrizia and Di Somma, Salvatore",
year = "2014",
abstract = "Background: Galectin-3 is a protein widely distributed in the heart, brain and blood vessels, and has a regulatory role in inflammation, immunology and cancer. Many studies demonstrated that the increased level of galectin-3 is associated with progressive fibrosis and stiffening of the myocardium. The aim of this study was to investigate the role of galectin-3 in patients with type 2 diabetes (T2D) and/or arterial hypertension (HT). Methods: Study population included 189 patients, with no coronary artery disease, divided into three groups: group 1 (T2D), group 2 (T2D+HT), and group 3 (HT). All subjects underwent routine laboratory tests, as well as specific biomarkers assessment [galectin-3, glycosylated hemoglobin (HbA(1c)), N- terminal fragment B-type natriuretic peptide (NT-proBNP)]. Cardiological evaluation included physical examination, transthoracic tissue Doppler echocardiography and stress echocardiography. Results: The results of this study demonstrated significantly increased levels of galectin-3, blood glucose, and HbA(1c) in group 2. Also, echocardiographicaly, left ventricular (LV) diameters and IVS thickness were increased in this group of patients. Furthermore, in the same cohort a positive correlation between galectin-3 and NT-pro BNP, and galectin-3 and LV mass were demonstrated. In addition, a negative correlation between galectin-3 and LV end-diastolic diameter was revealed. Conclusions: This study revealed that levels of galectin-3 were higher in patients with both T2D and HT, and correlated with LV mass, indicating the potential role of this biomarker for early detection of myocardial structural and functional alterations.",
publisher = "Walter de Gruyter Gmbh, Berlin",
journal = "Clinical Chemistry and Laboratory Medicine",
title = "Structural myocardial alterations in diabetes and hypertension: the role of galectin-3",
volume = "52",
number = "10",
pages = "1499-1505",
doi = "10.1515/cclm-2014-0265"
}

Seferović, J., Lalić, N. M., Floridi, F., Tesić, M., Seferović, P. M., Giga, V., Lalić, K., Jotić, A., Jovičić, S., Colak, E., Salerno, G., Cardelli, P.,& Di Somma, S.. (2014). Structural myocardial alterations in diabetes and hypertension: the role of galectin-3. in Clinical Chemistry and Laboratory Medicine
Walter de Gruyter Gmbh, Berlin., 52(10), 1499-1505.
https://doi.org/10.1515/cclm-2014-0265

Seferović J, Lalić NM, Floridi F, Tesić M, Seferović PM, Giga V, Lalić K, Jotić A, Jovičić S, Colak E, Salerno G, Cardelli P, Di Somma S. Structural myocardial alterations in diabetes and hypertension: the role of galectin-3. in Clinical Chemistry and Laboratory Medicine. 2014;52(10):1499-1505.
doi:10.1515/cclm-2014-0265 .

Seferović, Jelena, Lalić, Nebojša M., Floridi, Federico, Tesić, Milorad, Seferović, Petar M., Giga, Vojislav, Lalić, Katarina, Jotić, Aleksandra, Jovičić, Snežana, Colak, Emina, Salerno, Gerardo, Cardelli, Patrizia, Di Somma, Salvatore, "Structural myocardial alterations in diabetes and hypertension: the role of galectin-3" in Clinical Chemistry and Laboratory Medicine, 52, no. 10 (2014):1499-1505,
https://doi.org/10.1515/cclm-2014-0265 . .